| Autor: |
Maheshwari, Prachi Mantri, Maheshwari, Puneet, Bamoriya, Hemlata, Agrawal, Sheenu |
| Předmět: |
|
| Zdroj: |
Journal of Cardiovascular Disease Research (Journal of Cardiovascular Disease Research); 2023, Vol. 14 Issue 5, p1054-1056, 3p |
| Abstrakt: |
Background & Method: The aim of the study is to study the epidemiology of pre-term labour and its relation with parity. Weekly injections of micronized progesterone or vaginal micronized progesterone suppository of 100 mg. daily till 35 weeks starting from 28 weeks completed or whenever patients comes after that. Result:In present study out of 86 cases 4 were defaulters. The incidence of preterm labour in study group was 19.5 % that is out of 82 cases 16 had preterm labour. Out of 96 controls 32 had preterm labour giving an incidence of 33.33%.Maximally cases and controls belonged to parity 3 (34.1% and 38% respectively) showing that the risk of preterm labour is maximum in patients with parity 3. The chi-square statistic is 5.269. The p-value is < .049809. The result is significant at p < .05. Conclusion:A lot of dilemma remains in diagnosis and management strategy of preterm labour. Despite the newer technologies and drugs the rate of preterm birth has been increasing in past few decades managing a preterm neonate has a great financial load on world economy. So the studies are ongoing to find a best way to prevent preterm labour. At the recommended dose, micronized progesterone is a safe, effective, economical, minimally teratogenic and easily available to general public and it is FDA approved. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
